Clinical Trials Browser

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT04361162 2022-09-08

Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer

Phase 2 Active not recruiting

30 enrolled

Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms

NCT04258150 2022-03-31

TRIPPLE-R

Phase 2 Terminated

26 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT01896869 2020-05-19

FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer

Phase 2 Completed

83 enrolled 16 charts

Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Pancreatic Neoplasms

NCT01473940 2020-03-06

Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery

Phase 1 Completed

21 enrolled 14 charts

Gastrointestinal

Pancreatic Neoplasms

NCT00836407 2020-02-24

Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer

Phase 1 Completed

30 enrolled 9 charts

Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Pancreatic Neoplasms

Clinical Trials

Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer

XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer

Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer

Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer

NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

LAPTOP

Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer

INFLUENCE

VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer

TRIPPLE-R

FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer

Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery

Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer